NCT05185284 - Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19 | Biotech Hunter

Enrollment

217

Participants

Timeline

Start Date

August 11, 2021

Primary Completion Date

December 30, 2021

Study Completion Date

December 30, 2021

Conditions

COVID-19

Interventions

DRUG

Favipiravir

400 mg, lyophilizate for preparation of concentrate for solution for infusion

DRUG

Favipiravir

200 mg coated tablets

DRUG

Remdesivir

100 mg, lyophilizate for preparation of concentrate for solution for infusion

Trial Locations (6)

127015

"State Budgetary Institution of Healthcare of the City of Moscow City Clinical Hospital No. 24 of the Department of Healthcare of the City of Moscow", Moscow

153025

"Regional budgetary health care institution Ivanovo Clinical Hospital named after Kuvaevs", Ivanovo

Unknown

State Clinical Hospital №50, Moscow

Regional Clinic Hospital of Ryazan, Ryazan

Medical institute Ogarev Mordovia State university, Saransk

Smolensk clinical hospital №1, Smolensk

All Listed Sponsors

collaborator

Solyur Pharmaceuticals Group

UNKNOWN

lead

Promomed, LLC

OTHER